350 руб
Журнал «Технологии живых систем» №2 за 2013 г.
Статья в номере:
Биохимические маркеры мелкоклеточного рака легкого и паранеопластические синдромы
Ключевые слова: мелкоклеточный рак легкого паранеопластический синдром биохимические маркеры
Авторы:
Н.В. Любимова - д.б.н., вед. науч. сотрудник, лаборатория клинической биохимии, ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН. E-mail: biochimia@mtu-net.ru М.И. Давыдов - академик РАН и РАМН, директор, ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН
Аннотация:
Представлены данные по биохимическим маркерам мелкоклеточного рака легкого (МРЛ) и паранеопластических синдромов, ассоциированных с этим типом опухоли. Приведены современные представления о молекулярной структуре, биологической функции и особенностях синтеза и секреции маркеров, а также рассмотрены вопросы их применения в диагностике, мониторинге и прогнозе МРЛ.
Страницы: 34-49
Список источников
  1. Bajetta E., Ferrai L., Martinetti A. et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors // Cancer. 1999. V. 86. P. 858 - 865.
  2. Eriksson B., Oberg K., Stridsberg M. Tumor markers in neuroendocrine tumors // Digestion. 2000. V. 62.
    P. 33 - 38.
  3. Grandberg D., Wilander E., Oberg K., Skogseid B. Prognostic markers in patients with typical bronchical carcinoid tumors // J. Clin. Endocrinol. 2000. V. 85.  № 9. P. 3425 - 3430.
  4. Oberg K., Hellman P., Kwekkwboom D., Jelic S. ESMO Clinical recommendations for diagnostics, therapy and monitoring in neiroendocrine tumors of lungs and thymus // ESMO. 2007.
  5. Baudin E., Bidart J.M., Bachelit A. et al.Impact of chromogrannin A measurement in the work-up of neuroendocrine tumors // Ann. Oncology. 2001. V. 12. P. 79 - 82.
  6. Lamberts S.W., Hofland L.J., Nobels F.R. Neuroendocrine tumor markers // Front. Neuroendocrinology. 2001, V. 22. P. 309 - 339.
  7. Schmechel D., Marangos P.J., Brightman M. Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells // Nature. 1978.  V. 276. P. 834 - 836.
  8. Tapia F.J., Polak J.M., Barbosa A.J.A., Marangos P.J., Bloom S.R., Dermody C. et al.Neuron-specific enolase is produced by neuro-endocrine tumors // Lancet. 1981. V. 1. P. 808 - 811.
  9. McDonald T.J., Nilsson G., Vagne M., Ghatei M., Bloom S.R., Mutt V. A gastrin releasing peptide from the porcine nonantral gastric tissue // Gut. 1978.  V. 19. P. 767 - 774.
  10. Cuttitta F., Federko J., Gu J. et al. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man // J. Clin. Endocrinol. Metabol. 1988. V. 67. P. 576 - 583.
  11. Yamaguchi K., Abe K., Kameya T. et al.Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors // Cancer Res. 1983. V. 43. P.3932 - 3939.
  12. Preston S.R., Miller G.V., Primrose J.N. Bombesin-like peptides and cancer // Crit. Rev. Oncol. Hematol. 1996. V. 23. P. 225 - 238.
  13. Aoyagi K., Miyake Y., Kashiwakuma T. et al.Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation // Clin. Chem. 1995. V. 41. P. 537 - 543.
  14. Nordlund M.S., Fermer Ch., Nilsson O., Warren D.J., Paus E. Production and characterization of monoclonal antibodies for immunoassay of the lung cancer marker proGRP // Tumor Biol. 2007. V. 28. P. 100 - 110.
  15. Winther B., Moi P., Paus E., Reubsalt J.L. Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS // J. Sep. Sci. 2007. V. 30. P. 2638 - 2646.
  16. Wiedenmann B., Franke W.W., Kuhn C. et al.Synaptophysin: a marker protein for neuroendocrine cells and neoplasms // Proc. Natl. Acad. Sci. USA. 1986. V. 83.  P. 3500 - 3504.
  17. Wigge P., McMahon H.T. The amphiphysin family of proteins and their role in endocytosis at the synapse // Trends Neurosci. 1998. V. 21. P. 339 - 344.
  18. Valtorta F., Pennuto M., Bonanomi D., Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis - // Bioessays. 2004. V. 26. P. 445 - 453.
  19. Horai R., Nishihara H., Tateishi R. et al.Oat-cell carcinoma of the lung simultaneosly producing ACTH and serotonin // J. Clin. Endocrinol. Metabol. 1996. V. 37. P. 212 - 219.
  20. Song P., Sekhon H.S., Jia Y. et al.Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma // Cancer Res. 2003. V. 63.  P. 214 - 221.
  21. Benatar M., Blaes F., Johnston I. et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line // J. Neuroimmunol. 2001. V. 113. P. 153 - 162.
  22. O-Toole D., Grossman A., Gross D. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers // Neuroendocrinology. 2009. V. 90. P. 194 - 202.
  23. Akoun G.M., Scarna H.M., Milleron B.J. et al. Serum neuron-specific enolase. A marker for disease extent an response to therapy for small-cell cancer // Chest. 1985. V. 87. P. 39 - 43.
  24. Carney D.N., Marango P.J., Ihde D.C. et al. Serum neuron specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer // Lancet. 1982. I: P. 583 - 585.
  25. Johnson P.M.W., Joel S.P., Love S. et al. Tumor markers for prediction of survival and monitoring of remission in small cell lung cancer // Br. J. Cancer. 1993. V. 67. P. 760 - 766.
  26. Molina R., Auge J.M., Bosh X. et al.Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology // Tumor Biol. 2009. V. 30. P. 121 - 129.
  27. Satoh H., Ishikawa H., Kurishima K. et al.Cut-off levels of NSE to differentiate SCLC from NSCLC // Oncol. Rep. 2002. V. 9. № 3. P. 581 - 583.
  28. Schalhorn A., Fuerst H., Stieber P. Tumor markers in lung cancer // J. Lab. Med. 2001. V. 25. P. 353 - 361.
  29. Coskun H.S., Er O., Altinbas M. Serum tumor markers in small cell lung carcinoma patients treated with cyclophosphamide, epirubicin and vincristine com-bination // Turkish J. Cancer. 2005. V. 35. № 2. P. 81 - 87.
  30. Bremnes R.M., Sundstrom S., Aasebo U. et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year folow-up // Lung Cancer. 2003. V. 39. № 3. P. 303 - 313.
  31. Ebert W., Muley T., Trainer C. et al.Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC // Anticancer Res. 2002. V. 22. P. 1083 - 1089.
  32. Pinson P., Joos G., Bruseselle G., Pauwels R. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up os small-cell lung cancer // Respiration. 1997. V. 64. P. 102 - 107.
  33. Ando S., Suzuki M., Yamamoto N. The Prognostic Value of Both Neuron-specific Enolase (NSE) and Cyfra21-1 in Small Cell lung Cancer // Anticancer Res. 2004.  V. 24. P. 1941 - 1946.
  34. Bonner J.A., Sloan J.A., Rowland K.M. et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer // Clin. Cancer Res. 2000. V. 6. P. 597 - 601.
  35. Jorgensen L.G.M., Osterlind K., Genolla J. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centers // Br. J. Cancer. 1996. V. 74. P. 463 - 467.
  36. Molina R., Filella X., Auge J.M. ProGRP: a new biomarker for small cell lung cancer // Clin. Biochem. 2004. V. 37. P. 505 - 511.
  37. Schneider J., Philipp M., Velcovsky H.G. et al.Pro-gastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases // Anticancer Res. 2003. V. 23. P. 885 - 893.
  38. Stieber P., Dienemann H., Schalhorn A., Schmitt U.M. et al.Pro-gastrin-releasing peptide (ProGRP) ? a useful marker in small cell lung carcinomas // Anticancer Res. 1999. V. 19. P. 2673 - 2678.
  39. Takada M., Kusunoki Y., Masuda N. et al.Pro-gastrin-relesing peptide (31-98) as a tumor marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase // Br. J. Cancer. 1996. V. 73. P. 1227 - 1232.
  40. Niho S., Nishiwaki Y., Goto K. et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen // Lung Cancer. 2000. V. 27. № 3. P. 159 - 167.
  41. Schneider J., Philipp M., Salewski., Velcovsky H.G. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer // Clin. Lab. 2003. V. 49. № 1-2. P. 35 - 42.
  42. Wojcik E., Kulpa J.K., Sas-Korczynska B. et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer // Anticancer Res. 2008. V. 28. P. 3027 - 3034.
  43. Drivsholm L., Paloheimo L.I., Osterlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer // Br. J. Cancer. 1999. V. 81. № 4. P. 667 - 671.
  44. Sobol R.E., O-Connor D.T., Addison J. et al. Elevated serum chromogranin A concentrations in small-cell lung carcinoma // Ann. Intern. Med. 1986. V. 105. P. 698 - 700.
  45. Nobels F.R.E., Kwekkeboom D.J., Coompans W. Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparsion with Neuron-Specific Enolase and the alpha-Subunit of Glycoprotein Hormones // J. Clin. Endocrinol. Metabol. 1997. V. 82. № 8. P. 2622 - 2628.
  46. Giovanella L., Ceriani L., Bandera M. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase // Int. J. Biol. Markers. 2001. V. 16. № 1. P. 50 - 55.
  47. Lamy P.J., Grenier J., Kramar A., Pujol J.L.Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer // Lung Cancer. 2000. V. 29. № 30. P. 197 - 203.
  48. Shibayama T., Ueoka H., Nishii K. et al. Complementary roles of pro-gastrin-releasing peptid (ProGRP) and neuron specific enolase in diagnosis and prognosis of small-cell lung cancer (SCLC) // Lung Cancer. 2001. V. 32. № 1. P. 61 - 69.
  49. Pancoast H.K. Importance of careful roentgen-ray investigations of apical chest tumors // JAMA. 1924.
    V. 83. P. 1407 - 1411.
  50. Johnson D.H., Hainsworth J.D., Greco F.A. Pancoast-s syndrome and small cell lung cancer // Chest. 1982. V. 82. P. 602 - 606.
  51. Eagan R.T., Maurer L.H., Forcier R.J., Tulloh M. Small cell carcinoma of the lung: staging, paraneoplastic syndromes, treatment, and survival // Cancer. 1974. V. 33. № 2. P. 527 - 532.
  52. Richardson R.L., Greco F.A., Oldham R.K., Liddle G.W. Tumor products and potential markers in small cell lung cancer. 1978. V. 5. № 3. P. 253 - 262.
  53. Greco F.A. Paraneoplastic Syndromes // West. J. Medicine. 1986. V. 144. P. 604 - 606.
  54. Hansen M., Hammer M., Hummer L. ACTH, ADH and Calcitonin as markers of response and relapse in small-cell carcinoma of the lung // Cancer. 1980. V. 46. P. 2062 - 2067.
  55. Shepherd F.A., Laskey J., Evans W.K. et al. Cushing-s syndrome associated with ectopic corticotropin production and small-cell lung cancer // J. Clin. Oncol. 1992. V. 10. P. 21 - 27.
  56. Suyama K., Naito Y., Yoh K. et al. Development of Cushing`s Syndrome During Effective Chemotherapy for Small Cell Lung Cancer // Intern. Med. 2011. V. 50. P. 335 - 338.
  57. Schwartz W.B., Bennett W., Curelop S., Bartter F.C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone // Am. J. Med. 1957. V. 23. P.529 - 542.
  58. Kamoi K., Kurokawa I., Kasai H. et al.Asymptomatic hyponatremia due to inappropriate secretion of antidiuretic hormone as the first sign of a small cell lung cancer in as elderly man // Intern. Medicine. 1998.  V. 37. № 11. P. 950 - 954.
  59. List A.F., Hainsworth J.D., Davis B.W. et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer // J. Clin. Oncol. 1986. V. 4. № 8. P. 1191 - 1198.
  60. Radulescu D., Bunea D., Pripon S. Severe Paraneoplastic Hyponatremia and Hypoosmolality in a Patient with Small Cell Lung Carcinoma: Syndrome of Inappropriate Antidiuretic Hormone Secretion Versus Atrial Natriuretic Peptide or Both - // Clin. Lung Cancer. 2007. V. 8. № 6. P. 392 - 395.
  61. Tantisattamo E., Ng. R.C.K. Dual Paraneoplastic Syndromes: Small Cell Lung Carcinoma-related Oncogenic Osteomalacia, and Syndrome of Inappropriate Antidiuretic Hormone Secretion: Report of a Case and Review of the Literature // Hawaii Med. J. 2011. V. 70. P. 139 - 143.
  62. Vanhees S.L., Paridaens R., Vansteenkiste J.F. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small cell lung cancer: Case report and literature review // Ann. Oncology. 2000. V. 11. P. 1061 - 1065.
  63. Bork E., Hansen M., Urdal P. et al. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide // Eur. J. Cancer Clin. Oncol. 1988. V. 24. P. 1033 - 1038
  64. Silva O.L., Becker K.L., Primack A. et al. Increased serum calcitonin levels in bronchogenic cancer // Chest. 1976. V. 69. № 4. P. 495 - 499.
  65. Chapman C.J., Murray A., McElven J.E. et al. Autoantibodies in lung cancer - possibilities for early detection and subsequent cure // Thorax. 2008. V. 63. P. 228 - 233.
  66. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS // Lancet Neurol. 2008. V. 7. P. 327 - 340.
  67. Darnell R.B., Posner J.B. Paraneoplastic syndromes affecting the nervous system // Semin. Oncol. 2006.
    V. 33. P. 270 - 298.
  68. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS // J. Neurol. 2010. V. 257. P. 509 - 517.
  69. Kazarian M., Laird-Offringa I. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy // Mol. Cancer. 2011. V. 10. P. 33.
  70. Lang B., Vincent A. Autoimmunity to ion-chanels and other proteins in paraneoplastic disorders // Curr.
    Opin. Immunol. 1996. V. 8. P. 865 - 871.
  71. Maddison P., Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer // J. Neuroimmunol. 2008. V. 201-202. P. 159 - 162.
  72. Titulaer M.J., Klooster R., Potman M. et al. SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation with Survival // J. Clin. Oncol. 2009. V. 27. № 26. P. 4260 - 4267.
  73. Adamus G., Guy J., Shmied J.L., Arendt A., Hargrave P.A. Role of Anti-recoverin autoantibodies in cancer associated retinopathy // Invest. Ophtalmol. Vis. Sci. 1993. V. 34. P. 2626 - 2633.
  74. Alamowitch S., Graus F., Uchuya M. et al. Limbic encephalitis and small cell lung cancer. Clinical and immunological features // Brain. 1997. V. 120. P. 923 - 928.
  75. DeAngelis L.M., Posner J.B. Neurologic Compication of Cancer. 2nd // Oxford University Press. 2009. P. 236.
  76. Graus F., Elkon K.B., Cordon-Cardo C., Posner J.B. Sensory neuropathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor // Am. J. Med. 1986. V. 80. P. 45 - 52.
  77. Hainsworth J.D., Greco F.A. Neoplastic meningitis // J. Tenn. Ved. Assjc. 1981. V. 74. № 7. P. 510 - 513.
  78. Masayuki O., Dushin J., Shin J.Oh. Seropositive Myasthenia Gravis Associated with Small-Cell Lung Carcinoma // J. Clin. Neurol. 2011. V. 7. P. 43 -46
  79. Murray A., Chapman C., Healey G. et al. Technical validation of an autoantibody test for lung cancer // Ann. Oncol. 2010. V. 21. P. 1687 - 1693.
  80. Musunsuru K., Darnell R.B. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration // Ann. Rev. Neurosci. 2001. V. 24. P. 239 - 262.
  81. Satoh H., Ishikawa H., Kurishima K. et al.Cut-off levels of NSE to differentiate SCLC from NSCLC // Oncol. Rep. 2002. V. 9. № 3. P. 581 - 583.
  82. Lambert E.H., Eaton L.M., Rooke E.D. Defect of neuromuscular conduction associated with malignant neoplasms // Am. J. Physiol. 1956. V. 187. P. 612 - 613.
  83. Mason W.P., Graus F., Lang B. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic  syndrome // Brain. 1997.  V. 120. P. 1279 - 1300.
  84. Titulaer M.J., Wirtz. P.W., Willems L.N. et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome // J. Clin. Oncol. 2008. V. 26. P. 4276 - 4281.
  85. Graus F., Delattre J.Y., Antonie J.C. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes // J. Neurol. Neurosurg. Psyhiatry. 2004. V. 74. P. 1135 - 1140.
  86. Tscheransch M., Klotz M., Probst C. et al.Synaptophysin is an autoantigen in paraneoplastic neuropathy // Journal of neuroimmunology. 2008. V. 197. P. 81 - 86.
  87. Pittock S.J., Kryzer T.J., Lennon V.A. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome// Ann. Neurol. 2004. V. 56. P. 1280 - 1284.